Vancomycin
Weight Loss
Assaf Harofeh MCSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
6 Active assets in the Weight Loss cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Wellbutrin Mayo Clinic | Phase 4 | B |
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | B |
Xeomin® Tan Tock Seng Hospital | Phase 2/3 | CCC |
Cediranib City of Hope Medical Center | Phase 1 | CC |
DEXKETOPROFEN Laval University | N/A | D |
View all 9 →
Same molecule, other indications
Vancomycin is also rated in:
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →